OncoDaily Pulse

Aug 29, 2025, 22:14

Brad McGregor: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register via the link.

Co-Chair of VIRO

Images Name

Rana McKay
Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Brad McGregor

Dr. Brad McGregor is the Director of Clinical Research for the Lank Center for Genitourinary Oncology and a Medical Oncologist at the Dana-Farber Cancer Institute. He also serves as an Assistant Professor of Medicine at Harvard Medical School. Dr. McGregor’s clinical and research focus centers on optimizing treatment strategies for genitourinary cancers, with special expertise in advanced kidney cancer.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. McGregor will present on “Adjuvant Therapy: Patient Selection and Treatment Options”. His presentation will address:

Criteria and considerations for selecting patients who may benefit from adjuvant therapy.
Current and emerging treatment options available in the adjuvant setting for localized kidney cancer.
Evidence-based approaches to improve outcomes and reduce recurrence risk after surgery.
Integration of clinical trials and real-world data in guiding treatment decisions.

Drawing on his extensive clinical and research expertise, Dr. McGregor emphasizes personalized therapeutic approaches that balance efficacy with quality of life, aiming to improve outcomes in patients with localized kidney cancer.Drawing on his extensive clinical and research expertise, Dr. McGregor emphasizes personalized therapeutic approaches that balance efficacy with quality of life, aiming to improve outcomes in patients with localized kidney cancer.

Global Voices in Renal Oncology (VIRO) 2025

Brad McGregor cancer Dana-Farber Cancer Institute Harvard Medical School Lank Center for Genitourinary Oncology OncoDaily Oncology VIRO 2025. Global Voices in Renal Oncology

Why Is Financial Wellness Crucial for Physicians and Health Care Professionals?

BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing

10 Leading Experts Join OncoDaily Medical Journal Editorial Team

Top 10 Oncogrants of the Week: Fueling Cancer Research and Innovation

Soon-Shiong’s “Bioshield” Sparks Early Promise in Recurrent GBM, With 2 Near-CRs and 100% Disease Control